jRCT2071200085CompletedNot Applicable
Single-dose study of OMD-001 in healthy adult volunteers
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 8
- Primary Endpoint
- -
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Single Arm Study
- Intervention Model
- Single Assignment
- Primary Purpose
- Treatment Purpose
- Masking
- Open(masking Not Used)
Eligibility Criteria
- Ages
- 20age old over to 45age old under (—)
- Sex
- Male
Inclusion Criteria
- •Subjects who signed the written informed consent
- •Age>=20 and =<45 at time of consent
- •Body mass index (BMI) >=18.5 and <25.0
Exclusion Criteria
- •History of any significant drug allergy.
- •History of drug and/or alcohol abuse
- •History of renal, hepatic, cardiovascular, metabolic, respiratory disease.
- •A positive infection test and/or urine drug screen for substance of abuse at screening.
- •Subjects having taken an following drug and/or food.
- •Prescription and over-the-counter drugs : within the 14 days prior to the administration of investigational drug.
- •The following drugs known to cause photosensitivity : within the 14 days prior to the administration of investigational drug.
- •Tetracycline antibiotics, sulfonamides, new quinolone antibacterial agents, hypericin (Hypericum erectum extract)
- •Supplements containing 5-aminolevulinic acid : within the 14 days prior to the administration of investigational drug.
- •Foods containing St. John's Wort (St. John's Wort) : within the 14 days prior to the administration of investigational drug.
- •Consumption of alcohol: within the 3 days prior to the administration of investigational drug.
- •Subjects who participated in other clinical trials within 16 weeks prior to the administration of investigational drug.
- •Subjects who received 200 mL of blood (donated blood, etc.) within 4 weeks, 400 mL within 12 weeks, or 1200 mL or more within 1 year prior to the administration of investigational drug. and those who donated blood components within 2 weeks.
- •body weight : < 50 kg
- •Subjects who scheduled to visit another hospital during the clinical trial period
- •Subjects who had Clinically significant abnormality at screening phase and judged by the investigator to be unhealthy
- •Subjects who are judged by the investigator to be inappropriate for conducting this clinical study safely.
Outcomes
Primary Outcomes
-
Pharmacokinetics and Safety
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Withdrawn
Phase 1
A Phase 1 Single Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EARLI-001Cancer DiagnosisCancer - Any cancerACTRN12622001571763Earli Pty. Ltd.10
Completed
Phase 1
PC-SOD NE(Phase I) -Single Dose Study in healthy volunteersidiopathic pulmonary fibrosisJPRN-UMIN000008920TT Bio Pharma Co., LTD.24
Completed
Not Applicable
Single-dose study of M707102 in healthy subjectsActinic keratosisjRCT2071230090Maruho Co.,Ltd.16
Recruiting
Phase 1
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populationson Small Cell Lung CancerNon Small Cell Lung CancerCancer - Lung - Non small cellACTRN12621000848808EQRx, Inc30
Active, not recruiting
Not Applicable
Single and multiple dose study of M136101 in healthy subjects.Dry eye with meibomian gland dysfunction/ChalazionjRCT2031240458Maruho Co.,Ltd.24